ArticleFrontiers in pharmacology2026
Lessons from the STOPPCog criteria: prevalence of potentially inappropriate medications for cognition and their association with a cognitive status - a cross-sectional study.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Potentially inappropriate medications (PIMs), are common among residents of long-term care institutions (LTCIs) and may contribute to cognitive impairment (CIm). STOPPCog criteria, developed in 2025, support the identification of PIMs relevant to cognition and accuracy of dementia treatment. Objectives: The study aimed to identify PIMs according to the STOPPCog criteria among residents of long-term care institutions in Poland, and to assess the association between CIm and exposure to specific drug classes. Patients and Methods: This is a multicenter cross-sectional study in four LTCIs. Medication lists were reviewed using STOPPCog criteria and anticholinergic burden scales. Cognitive status was assessed with the Mini-Mental State Examination (MMSE), and CIm was defined using a conventional cut-off. We compared exposure frequencies between residents with and without CIm and explored factors associated with MMSE using regression models adjusted for key demographic and clinical variables and facility effects. Results: Of 204 residents, 133 (65.2%) had at least one STOPPCog-listed medication on their medication list. Drugs with anticholinergic burden (ACB) (54.9%), especially one subgroup - antipsychotics (39.2%), were most frequently used within the study sample. Antipsychotics were the only drug class significantly associated with CIm independently of sex, age, comorbidity burden, and facility (p < 0.001). The majority of residents with a previous diagnosis of dementia in their medical records and consequently dementia-specific pharmacotherapy had severe CIm. Conclusion: There is a high prevalence of PIMs among LTCIs residents. Antipsychotic deprescribing and early diagnosis of CIm should be further evaluated in future prospective studies and clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.